{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:32:52Z","timestamp":1782981172213,"version":"3.54.5"},"reference-count":26,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the impact of discrepancy between prescribed and recommended fixed 200\u2009mg dose (P-F discrepancy) on immune-related adverse events (irAEs) and treatment efficacy in patients with advanced melanoma and NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 177 patients with advanced melanoma or non-small cell lung cancer (NSCLC) who received at least one cycle of single-agent pembrolizumab. We defined P-F discrepancy as the differences between prescribed pembrolizumab dose and 200\u2009mg recommended dose, expressed in percentages. Our primary outcome was immune-related adverse events (irAEs), and our secondary outcomes included overall survival (OS) and progression free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median P-F discrepancy was \u201321.5%, with the 25th and 75th percentile at \u201332% and \u20135.0% respectively. ROC curve analyses did not show any optimal cutoffs to prognosticate irAEs (AUC\u2009=\u20090.558 for all patients) or cancer mortality (AUC\u2009=\u20090.583 for melanoma; AUC\u2009=\u20090.539 for NSCLC) in either cancer type. Separate multivariable Cox analyses suggested no statistically significant association between P-F discrepancy and overall survival in patients with melanoma (HR 1.012, 95%CI 0.987\u20131.038, P\u2009=\u20090.362) or NSCLC (HR 0.998, 95%CI 0.978\u20131.019, P\u2009=\u20090.876).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was no optimal pembrolizumab cut-off point to predict irAEs or treatment efficacy. We supported the use of weight-based pembrolizumab dosing, given the potential cost-saving and no differences in terms of irAEs or treatment efficacy in patients with advanced melanoma or NSCLC. Future studies on province- or national-level would be important to validate our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220984252","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T01:17:43Z","timestamp":1611883063000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-5206","authenticated-orcid":false,"given":"A","family":"Kartolo","sequence":"first","affiliation":[{"name":"Cancer Centre of Southeastern Ontario, Kingston, ON, Canada"},{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Holstead","sequence":"additional","affiliation":[{"name":"Cancer Centre of Southeastern Ontario, Kingston, ON, Canada"},{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Hopman","sequence":"additional","affiliation":[{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Young","sequence":"additional","affiliation":[{"name":"Cancer Centre of Southeastern Ontario, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Baetz","sequence":"additional","affiliation":[{"name":"Cancer Centre of Southeastern Ontario, Kingston, ON, Canada"},{"name":"Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"bibr1-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"bibr2-1078155220984252","unstructured":"U.S. National Library of Medicine. Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990\/MK-3475-001\/KEYNOTE-001)(KEYNOTE-001). ClinicalTrials.gov Identifier: NCT01295827, 2011. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01295827 (accessed 4 August 2020)."},{"key":"bibr3-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011"},{"key":"bibr4-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"bibr5-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"bibr6-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"bibr7-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.tps3094"},{"key":"bibr8-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"bibr9-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12139"},{"key":"bibr10-1078155220984252","unstructured":"Cancer Care Ontario. Drug formulary: pembrolizumab. Available at: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/monograph\/44411 (accessed 4 August 2020)."},{"key":"bibr11-1078155220984252","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development. CTEP. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (accessed 4 August 2020)."},{"key":"bibr12-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"bibr13-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0242-5"},{"key":"bibr14-1078155220984252","first-page":"1","volume":"0","author":"Jang A","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"bibr15-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2888"},{"key":"bibr16-1078155220984252","unstructured":"Cancer Care Ontario Beyond-Use Date Recommendations Report. Cancer Care Ontario. 2018. Available at: https:\/\/www.cancercareontario.ca\/en\/content\/cancer-care-ontario-beyond-use-date-recommendations-report (accessed 10 November 2020)."},{"key":"bibr17-1078155220984252","first-page":"9","volume":"3","author":"McMichael DM","year":"2011","journal-title":"Am J Pharm Benefits"},{"key":"bibr18-1078155220984252","first-page":"311","volume":"3","author":"Carey ET","year":"2011","journal-title":"Am J Pharm Benefits"},{"key":"bibr19-1078155220984252","first-page":"46","volume":"6","author":"Ho KV","year":"2016","journal-title":"J Hematol Oncol Pharm"},{"key":"bibr20-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"bibr21-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004"},{"key":"bibr22-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189"},{"key":"bibr23-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz449.001"},{"key":"bibr24-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.11.013"},{"key":"bibr25-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2011.01052.x"},{"key":"bibr26-1078155220984252","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8188-0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220984252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220984252","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220984252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:27Z","timestamp":1777688667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220984252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1177\/1078155220984252"],"URL":"https:\/\/doi.org\/10.1177\/1078155220984252","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}